Eric Y. Chuang

Vice President & General Director
Biomedical Technology and Device Research Laboratories
Industrial Technology Research Institute
 

Eric Y Chuang received his doctorate in cancer biology with toxicology and molecular genetics as two sub-specialties from Harvard University in 1997 and his doctoral thesis was to study radiation-induced mutagenesis in human cells. After graduation, he stayed at Harvard as a postdoctoral fellow for one year. He then joined the Radiation Biology Branch of National Cancer Institute (NCI), National Institutes of Health (NIH) as an IRTA fellow to study radiogenomics in Bethesda, MD, USA. Next, he became the Head of Microarray Laboratory for Radiation Oncology Sciences Program at NCI; his lab was to develop new initiatives that utilized state-of-the-art microarray technologies for studying radiation oncology related research projects. After working at the NIH for several years, he took a faculty position at National Taiwan University (NTU). In 2009, he joined the Radiation Research Program of Division of Cancer Treatment and Diagnosis at NCI as a Program Director to oversee a portfolio of NIH grants that included radiation-induced signaling pathways, molecular mechanisms and normal tissue injuries as well as radiation related genomic studies. In 2011, he returned to NTU and was serving as the Director of Graduate Institute of Biomedical Electronics and Bioinformatics (BEBI) in 2012-2018. Dr. Chuang received his Executive MBA degree in International Business Management from NTU in June 2017. Currently, he is a Professor of BEBI at NTU and serving as the Vice President & General Director, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan. Being an expert in genomic technologies, bioinformatics, cancer, radiation biology & oncology, biomedical engineering, and precision medicine, he has published more than 160 peer-reviewed papers in related fields. Moreover, Dr. Chuang has been serving as an editorial board member of Scientific Reports and the Editor-in-Chief of Translation Cancer Research.

Speech title & Synopsis

Establish an Interdisciplinary Collaboration Platform for Biomedical Innovations in Taiwan

Solving the challenges that biomedical innovation faces today requires combining biotechnology (BIO) with information and communication technology (ICT). These smart technologies together provide crucial validation and drive innovation, supporting the advancement of next generation preventive, diagnostic, and therapeutic medical solutions.

In order to smoothly integrate these two seemingly separate industries, the Interdisciplinary Collaboration Platform for Biomedical Innovations provides a meeting point for experts from various fields, including domestic and international companies, medical institutions, and capital markets. The platform aims to create an ecosystem that will promote research and development, inspire the creation of innovative medical solutions, and strengthen international connections.

Through this platform, the Biomedical Technology and Device Research Laboratory (BDL) of Industrial Technology Research Institute (ITRI) is taking a leading role in the future of healthcare, acting as a crucial bridge between the healthcare and the ICT industries. However, beyond just connecting medicine and technology, BDL aims to elevate Taiwan’s medical technology industry to the global stage.